Can a Late Interception by Circulating Tumor DNA Deliver a Win in Estrogen Receptor-Positive Early Breast Cancer?

J Clin Oncol. 2022 Aug 1;40(22):2395-2397. doi: 10.1200/JCO.22.01026. Epub 2022 Jun 4.

Authors

David W Cescon¹, Kevin Kalinsky², Angela M DeMichele³

Affiliations

¹ Department of Medical Oncology, Princess Margaret Cancer Center, University Health Network and University of Toronto, Toronto, ON, Canada.
² Winship Cancer Institute at Emory University, Atlanta, GA.
³ Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

PMID: 35658519
DOI: 10.1200/JCO.22.01026

No abstract available

Publication types

Editorial
Comment

MeSH terms

Breast Neoplasms* / genetics
Breast Neoplasms* / pathology
Circulating Tumor DNA* / genetics
Female
Humans
Prognosis
Receptor, ErbB-2
Receptors, Estrogen / genetics

Substances

Circulating Tumor DNA
Receptors, Estrogen
Receptor, ErbB-2

Grants and funding

R01 CA208273/CA/NCI NIH HHS/United States